Marinus Pharma (MRNS) Tops Q1 EPS by 31c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Marinus Pharma (MRNS) Tops Q1 EPS by 31c

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

May 12, 2022 4:04 PM EDT

ZTALMY® (ganaxolone) U.S. commercial launch on track for July 2022 Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 Site activations advance in Phase 3 TrustTSC trial in tuberous sclerosis complex; topline data anticipated first quarter 2024 Patient dosing underway for Phase 1 trial of ganaxolone second generation formulation; topline data on track for mid-2022 readout Continue to strengthen cash position with Oaktree Capital drawdown and expectation to monetize priority review voucher Marinus to host conference call today at 4:05 p.m.... More